-
2 months ago | 
targetedonc.com | Paolo Tarantino
Paolo Tarantino, MD, PhD, medical oncologist and clinical fellow at Dana-Farber Cancer Institute, discusses the approval of the oral therapy elacestrant (Orserdu) for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations. Based on the phase 3 EMERALD trial (NCT03778931), the FDA approved elacestrant for these patients who had previously received standard therapies, including at least 1 line of endocrine therapy.
-
2 months ago | 
acsjournals.onlinelibrary.wiley.com | Adrienne G. Waks |Paolo Tarantino |Emily Chen |Rachel A. Freedman
INTRODUCTION Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15%–20% of invasive breast cancers and is an unfavorable prognostic factor.1 The administration of HER2-directed therapy has transformed outcomes for patients who have HER2-positive breast cancer.
-
Jan 13, 2025 | 
cancernetwork.com | Paolo Tarantino |Matteo Lambertini
January 13, 2025By Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024. Following the 2024 San Antonio Breast Cancer Symposium (SABCS), Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD, co-hosted a live X Space with CancerNetwork® and spoke about updated trial findings that may impact the breast cancer treatment paradigm.
-
Nov 25, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
November 25, 2024By Along with the Oncology Brothers, Paolo Tarantino, MD, shares insights on what has been learned about proactive monitoring and management of adverse reactions effects (AEs) to elacestrant, emphasizing strategies to help patients remain on therapy while maximizing their quality of life. What has been learned about proactive monitoring and management for adverse reactions to elacestrant that can help keep patients on therapy and maximize their quality of life?
-
Nov 25, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
November 25, 2024 By Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community...
-
Nov 25, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
Emerging Data on Oral SERDSAlong with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective estrogen receptor degraders (SERDs), including elacestrant, highlighting trials exploring its combination with other therapies and its potential in different patient populations. What are some ongoing studies investigating novel uses of oral SERDs, including those of elacestrant?
-
Nov 25, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
November 25, 2024By Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and discusses the ongoing research into the prognostic significance of these co-occurring mutations in metastatic breast cancer. How frequently are ESR1m found to co-occur with other alterations (eg, PIK3CA, TP53, or HER2-low expression)?
-
Nov 25, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
November 25, 2024By Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide the selection of optimal candidates for elacestrant treatment.
-
Nov 22, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Paolo Tarantino
Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBCAlong with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- metastatic breast cancer, particularly in patients with ESR1 mutations. Please give a brief overview of the phase 3 EMERALD study
-
Nov 15, 2024 | 
oncologynewscentral.com | Paolo Tarantino
The pace of newly approved drugs in oncology has been steadily accelerating over the course of the past decades, with multiple novel compounds being marketed every year across tumor types. However, patients with cancer can only benefit from these new drugs if they are considered by their physicians and in the absence of relevant obstacles to their access. This year, the Oncology News Central editorial team released its third annual Oncology Drug Report.
